Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Income: 2021-2025

Historic Net Income for InMed Pharmaceuticals (INM) over the last 5 years, with Sep 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' Net Income fell 2.92% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 20.58%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.34% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Net Income is -$1.7 million, which was up 3.43% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' Net Income's 5-year high stood at -$336,591 during Q2 2023, with a 5-year trough of -$7.9 million in Q2 2022.
  • For the 3-year period, InMed Pharmaceuticals' Net Income averaged around -$1.8 million, with its median value being -$1.8 million (2025).
  • Its Net Income has fluctuated over the past 5 years, first soared by 95.72% in 2023, then tumbled by 473.57% in 2024.
  • MRQ analysis of 5 years shows InMed Pharmaceuticals' Net Income stood at -$4.3 million in 2021, then soared by 51.01% to -$2.1 million in 2022, then increased by 29.55% to -$1.5 million in 2023, then tumbled by 74.20% to -$2.6 million in 2024, then skyrocketed by 32.94% to -$1.7 million in 2025.
  • Its Net Income was -$1.7 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.1 million in Q1 2025.